AG-2/AGR2 Antibody

Product Discontinued

AG-2/AGR2 Antibody Summary

• Immunogen: Peptide with sequence C-GAKKDTKDSRPK corresponding to internal region according to NP_006399.1.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: AGR2
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • Peptide ELISA Detection limit 1:16000
  • Western Blot 0.01-0.03 ug/ml
• Application Notes: Western blot: Approx 18kDa band observed in Human Colon, Duodenum and Lung lysates (calculated MW of 20.0kDa according to NP_006399.1).
• Control:

  Human Duodenum Whole Tissue Lysate (Adult Whole Normal)

Reactivity Notes

Predicted cross-reactivity based on sequence identity:Humna, Mouse, Canine.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris (pH 7.3), 0.5% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.5 mg/ml
• Purity: Immunogen affinity purified

Alternate Names for AG-2/AGR2 Antibody

• AG2
• AG-2
• AG2member 17
• AGR2
• anterior gradient 2 homolog (Xenopus laevis)
• anterior gradient homolog 2 (Xenopus laevis)
• GOB-4
• hAG-2
• HPC8
• PDIA17
• secreted cement gland homolog

Background

Agrin is an essential extracellular matrix component which promotes clustering of nicotinic acetylcholine receptors (nAChRs) and other proteins during development at the neuromuscular junction. Agrin, MuSK and Rapsyn are all essential components for AChR aggregation, through an unknown mechanism. The C-terminal region of agrin is released into the medium, interacts with receptors on the muscle surface and induces AChR aggregation. The central region contains two O-linked glycosylation sites and a domain homologous to domain III of laminin. The N-terminal region anchors agrin to the extracellular matrix via other basal membrane components. This region also contains a protease inhibitor domain and glycosaminoglycan attachment sites; increasing the predicted MW from 200kDa to ~600kDa.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for AG-2/AGR2 Antibody (NB100-55405)(1)

Publication using NB100-55405

• Innes HE, Liu D, Barraclough R et al. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer 2006-04-10 [PMID: 16598187]

Bioinformatics

• Gene Symbol: AGR2
• Entrez:
  • 10551(Human)
  • 23795(Mouse)
• Uniprot:
  • O95994(Human)